OncoMatch/Clinical Trials/NCT07081022
JS203 Combination Regimens in B-Cell Non-Hodgkin's Lymphoma
Is NCT07081022 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including JS203 in combination with gemcitabine and oxaliplatin and JS203 in combination with ifosfamide, carboplatin and etoposide for b-cell non-hodgkin's lymphoma.
Treatment: JS203 in combination with gemcitabine and oxaliplatin · JS203 in combination with ifosfamide, carboplatin and etoposide · JS203 in combination with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone · JS203 combined with lenalidomide — To evaluate the preliminary efficacy of JS203 combined with standard regimens in patients with B-cell Non-Hodgkin's lymphoma
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Chemotherapy
Other
Cancer type
Non-Hodgkin Lymphoma
Biomarker criteria
Required: CD20 overexpression
B-cell non-Hodgkin's lymphoma expressing CD20 antigen
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Cannot have received: CD20-CD3 bispecific antibody
Previously received CD20-CD3 bispecific antibody treatment
Cannot have received: allogeneic hematopoietic stem cell transplantation
Previous allogeneic hematopoietic stem cell transplantation
Cannot have received: solid organ transplantation
Previous solid organ transplantation
Lab requirements
Blood counts
Kidney function
Liver function
Acceptable organ function at screening
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07081022 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior CD20-CD3 bispecific antibody, allogeneic hematopoietic stem cell transplantation, solid organ transplantation disqualifies patients from enrollment.
Does this trial require CD20?
Yes, CD20 overexpression is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 80 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages